Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06564246 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Study Evaluating The Role of Vonoprazan Versus Pantoprazole in Patients With Gastroesophageal Reflux Disease

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 5, 2024 (before its estimated August 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Eligibility criteria expanded, about 1 wordv7 See this version in full on ClinicalTrials.gov ↗
  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Sep 2024 to Sep 18, 2024 · Eligibility criteria revised · Site details revisedv6 Show 3 more changesShow less
    • Start date changed from estimate of Sep 2024 to Sep 18, 2024
    • Eligibility criteria revised
    • Site details revised

    See this version in full on ClinicalTrials.gov ↗

  3. Interventions: Vonoprazan 20 mg (vonseca) versus Pantoprazole 40 mg (Pantoloc) (Drug) to Vonoprazan 20 mg versus Pantoprazole 40 mg (Drug) Eligibility criteria shortened, about 3 wordsv5 Show 1 more changeShow less
    • Eligibility criteria shortened, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  4. Re-verified, no change to tracked fieldsv4
  5. Start date: Aug 2024 to Sep 2024v3
  6. Interventions: Vonoprazan and placebo of pantoloc versus Pantoprazole 40 mg (Pantoloc) and placebo of vonseca (Drug) to Vonoprazan 20 mg (vonseca) versus Pantoprazole 40 mg (Pantoloc) (Drug) Secondary endpoint revised · Publications: details revised at 10 of 11 entriesv2 Show 2 more changesShow less
    • Secondary endpoint revised
    • Publications: details revised at 10 of 11 entries

    See this version in full on ClinicalTrials.gov ↗

  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study aims to investigate the possible efficacy of vonoprazan versus Pantoprazole in patients with gastroesophageal reflux disease.
Trial Details
NCT Number NCT06564246
Lead Sponsor Tanta University
Conditions Gastroesophageal Reflux Disease (GERD)
Enrollment 44 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov